Clinical guidance for the use of trazodone in major depressive disorder and concomitant conditions: pharmacology and clinical practice.


Journal

Rivista di psichiatria
ISSN: 2038-2502
Titre abrégé: Riv Psichiatr
Pays: Italy
ID NLM: 0425672

Informations de publication

Date de publication:
Historique:
entrez: 6 8 2019
pubmed: 6 8 2019
medline: 25 1 2020
Statut: ppublish

Résumé

To provide a review of the clinically relevant evidence pertaining to the use of trazodone in major depressive disorder. Medline and Cochrane Library searches were searched using the keywords 'trazodone' AND 'depression', to identify the most relevant literature pertinent to the pharmacological properties of trazodone and its use in clinical practice. Articles that were selected included basic pharmacology papers, clinical trials, clinical practice guidelines, and reviews. Related references were cross checked. European and United States prescribing information was reviewed as well. An effort was made to give weight to the information that was most relevant for daily clinical practice. Trazodone is an antidepressant with a mechanism of action that remains innovative and with a favorable profile for the treatment of depression. The appropriate antidepressant doses are usually 150-300 mg/day and are often higher than the doses that are used when trazodone is prescribed to augment the antidepressant effect of another medication, for instance when trazodone is prescribed to address insomnia in a patient treated with an SSRI. Trazodone is usually well tolerated and has a low risk of anticholinergic side effects, weight gain and sexual side effects. Trazodone is an established medication that is efficacious for the treatment of a broad array of depressive symptoms, including symptoms that are less likely to respond to other antidepressants (e.g. SSRI), such as insomnia. As an antidepressant, trazodone has proven as efficacious as the tricyclic and second-generation antidepressants and is tolerated relatively well. Trazodone may be helpful for patients with major depression and comorbid insomnia, anxiety or psychomotor agitation. Trazodone is efficacious antidepressants with a relatively low risks of side effects such as weight gain, sexual or anticholinergic effects (such as constipation, urinary retention, dry mouth). In addition to being able to control a wide range of depressive symptoms, trazodone may improve sleep and be particularly helpful for patients whose symptoms of depression include insomnia.

Identifiants

pubmed: 31379379
doi: 10.1708/3202.31796
doi:

Substances chimiques

Antidepressive Agents, Second-Generation 0
Delayed-Action Preparations 0
Trazodone YBK48BXK30

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

137-149

Auteurs

Alessandro Cuomo (A)

Dipartimento di Medicina Molecolare e dello Sviluppo, Università di Siena - Divisione di Psichiatria, Sistema Sanitario Nazionale della Lombardia, Mantova.

Andrea Ballerini (A)

Sod di Psichiatria, Azienda Ospedaliero-Universitaria Careggi, Firenze.

Amalia Cecilia Bruni (AC)

Centro Regionale di Neurogenetica, Lamezia Terme, Azienda Sanitaria Provinciale di Catanzaro.

Paolo Decina (P)

Private practice.

Guido Di Sciascio (G)

Dipartimento di Salute Mentale, ASL Bari.

Alessio Fiorentini (A)

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano.

Francesco Scaglione (F)

Dipartimento di Oncologia ed Emato-oncologia, Università di Milano.

Claudio Vampini (C)

Servizio di Psichiatria e Psicogeriatria, Clinica San Francesco, Verona.

Andrea Fagiolini (A)

Dipartimento di Medicina Molecolare e dello Sviluppo, Università di Siena.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH